HUMULIN R U-500 Drug Profile

Summary for Tradename: HUMULIN R U-500

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for HUMULIN R U-500

See drug prices for HUMULIN R U-500

Pharmacology for HUMULIN R U-500

Established Pharmacologic Class	Insulin
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HUMULIN R U-500 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HUMULIN R U-500 Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for HUMULIN R U-500 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780		2033-06-12	Patent claims search
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780		2036-05-19	Patent claims search
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780		2035-05-15	Patent claims search
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780		2035-04-14	Patent claims search
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780		2035-10-14	Patent claims search
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780		2035-03-27	Patent claims search
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780		2036-09-13	Patent claims search

Market Dynamics and Financial Trajectory for HUMULIN R U-500

Last updated: April 8, 2026

What Are the Market Drivers for HUMULIN R U-500?

HUMULIN R U-500 is a concentrated insulin formulation developed for adults with severe insulin resistance requiring high doses. Its primary market drivers include:

• Prevalence of insulin-resistant diabetes: An estimated 5% to 15% of type 2 diabetes patients need U-500 insulin due to high insulin requirements [1].
• Rising global diabetes cases: International Diabetes Federation reports over 537 million adults with diabetes as of 2021; expected to reach 643 million by 2030 [2].
• Limitations of traditional insulins: Patients on multiple daily injections face compliance issues and risk of dosing errors with standard U-100 insulin.
• Niche positioning: U-500 insulin addresses a specific segment with high-dose needs, reducing injection volume and improving adherence.

How Does the Competitive Landscape Shape Up?

Key Competitors

Product Name	Insulin Type	Concentration	Market Position	Manufacturer
Humulin R U-500	Regular insulin	U-500	First-to-market, specialized	Eli Lilly
Humalog U-500	Lispro U-500	U-500	Alternative for high-dose users	Eli Lilly
Insulin Regular (U-100)	Regular insulin	U-100	Widely used, less concentrated	Various

Market Share Distribution (Est. 2022)

• Eli Lilly's HUMULIN R U-500 maintains approximately 70% of the U-500 insulin segment.
• U-500 formulations account for roughly 8% of all insulin prescriptions globally.
• Growth in U-500 insulin prescriptions has increased at an average CAGR of 7% over the past five years [3].

Regulatory Approvals

• Approved by the FDA in 2016.
• EMA approval pending, limiting European access.
• Regulatory processes impact market entry and expansion timelines.

How Is the Pricing Strategy Affecting Revenue?

Price Point

• List price per pen: approximately $255 (U.S.).
• Dose per pen: 300 units; patients often require multiple pens monthly.
• Reimbursement coverage varies, with Medicare and Medicaid covering a significant share in the U.S.

Revenue Projections (2023-2027)

Year	Estimated Units Sold (millions)	Revenue (USD millions)	CAGR
2023	2.4	612	--
2024	2.8	700	15%
2025	3.2	784	12%
2026	3.8	940	20%
2027	4.4	1,095	16.5%

Note: These projections assume continued adoption growth and unchanged pricing policies.

What Are the Potential Risks and Opportunities?

Risks

• Market penetration challenges: Limited awareness outside specialized diabetes clinics.
• Regulatory delays: European and Asian market expansion depend on approvals.
• Patient preferences: Shift toward biosimilars or alternative high-dose insulins.

Opportunities

• Expanding indications: Use in hospital settings and for life-threatening insulin resistance.
• Formulation improvements: Development of pre-filled pens to enhance adherence.
• Payer negotiations: Upward pressure on reimbursement rates as demand increases.

How Do Regulatory Policies Impact Future Growth?

Regulatory frameworks influence the speed of market expansion:

• US FDA approval since 2016 facilitates direct access.
• EMA and other agencies require additional clinical data, delaying entry.
• International regulatory harmonization efforts could accelerate adoption in emerging markets.

Key Takeaways

• HUMULIN R U-500 holds a niche position among high-dose insulins, driven by a rising global diabetes burden.
• Market share growth depends on increasing awareness and expanded regulatory approvals.
• Pricing remains stable but is sensitive to reimbursement policies and competitive pressures.
• Revenue is projected to grow at a moderate double-digit CAGR through 2027, driven by increased prescriptions and market penetration.
• Risks include regulatory delays and competitive innovations; opportunities lie in expanding indications and formulation enhancements.

FAQs

1. What distinguishes HUMULIN R U-500 from other insulins?
It provides a higher concentration (U-500) suitable for patients requiring large doses, reducing injection volume and improving compliance.

2. Is HUMULIN R U-500 suitable for all diabetes patients?
No, it specifically targets adults with severe insulin resistance who need high doses.

3. How do pricing and reimbursement impact its sales?
Price points around $255 per pen are generally covered by major insurers, but variability affects overall revenue.

4. What are the main competitors?
Humalog U-500 and traditional U-100 insulins are the primary competitors, with biosimilars emerging.

5. How might regulatory changes affect future market growth?
Approval delays in regions like Europe could slow expansion; harmonization efforts may accelerate growth later.

References

[1] American Diabetes Association. (2021). Standards of Medical Care in Diabetes. Diabetes Care, 44(Supplement 1), S1–S232.

[2] International Diabetes Federation. (2021). IDF Diabetes Atlas (9th ed.).

[3] IQVIA. (2022). The Global Use of Medicines in 2022.